Suchergebnisse - "Hardi, Apor"

PubPharm (7)

1

Calreticulin : Pathophysiology of an unusual gain-of-function and its clinical consequences

enthalten in: Magyar onkologia | 2022

von Kozma, A. | Meggyesi, N. | Hardi, A. | +4

2

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma : Real World Data From Seven Hungarian Centers

enthalten in: Pathology oncology research : POR | 2022

von Szita, V. | Mikala, G. | Kozma, A. | +12

3

Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime

enthalten in: Orvosi hetilap | 2021

von Hardi, A. | Varga, G. | Nagy, Z. | +9

4

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients : Results of Real-Life Data From 11 Hungarian Centers

enthalten in: Pathology oncology research : POR | 2021

von Varga, G. | Dávid Tóth, A. | Réka Szita, V. | +26

5

Identification of the best-suited donor for generating virus-specific T cells

enthalten in: Vox sanguinis | 2020

von Tasnády, S. | Karászi, �. | Szederjesi, A. | +10

6

Identification of the best‐suited donor for generating virus‐specific T cells

enthalten in: Vox Sanguinis | 2020

von Tasnády, S. | Karászi, �. | Szederjesi, A. | +10

7

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

enthalten in: Journal of immunotherapy (Hagerstown, Md. : 1997) | 2018

von Kállay, K. | Kassa, C. | Réti, M. | +10

1
[1]